Q-omics provides the consensus-scored DEPDC4 profile across patient tissues and cancer cell-line models. DEPDC4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, DEPDC4 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, DEPDC4 RNA expression shows 19,609 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, HNSC, and UVM as cancer lineages where DEPDC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEPDC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEPDC4 survival associations across molecular data types. DEPDC4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEPDC4 RNA expression–survival associations across cancer types. High DEPDC4 expression shows unfavorable associations in ACC, SKCM, COAD and UVM, but favorable associations in UCS and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for DEPDC4 RNA expression.
This table summarizes DEPDC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for DEPDC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEPDC4 shows lower tumor expression in KICH, KIRC and THCA and higher tumor expression in HNSC, LUAD and LUSC. The HNSC box plot shows higher DEPDC4 RNA expression in tumor versus normal tissue (log2 FC = +0.346, t-test p < 0.001).
This table shows molecular features associated with DEPDC4 in patient tissues and cancer cell lines. In patient samples, DEPDC4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DEPDC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
